Indeed, small-sample studies and a pooled analysis indicate that for NSCLC patients harboring EGFR mutations, the addition of anlotinib following progression on EGFR TKI therapy could safely overcome resistance, though the efficacy might be modest. This evidence concerns the gene EGFR and non-small cell lung carcinoma.